Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 11/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | NLRP3 | Q96P20 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2014987 | 0.87 | SMN1; SMN2 (0.64) | SMN1; SMN2MAPTPOLBMTORALDH1A1 | |
| SCHEMBL2016657 | 0.85 | MAPT (0.53) | SMN1; SMN2MAPTPOLBALDH1A1HSP90AA1 | |
| SCHEMBL2012824 | 0.80 | SMN1; SMN2 (0.45) | SMN1; SMN2MAPTPOLBMTORALDH1A1 | |
| SCHEMBL2015126 | 0.80 | MAPT (0.47) | SMN1; SMN2MAPTPOLBMTORALDH1A1 | |
| SCHEMBL2013308 | 0.75 | MAPT (0.41) | SMN1; SMN2MAPTPOLBALDH1A1HSP90AA1 | |
| SCHEMBL2011806 | 0.75 | MAPT (0.53) | SMN1; SMN2MAPTPOLBALDH1A1HSP90AA1 | |
| SCHEMBL2014050 | 0.73 | MAPT (0.40) | MAPTPOLBALDH1A1HSP90AA1KMT2A | |
| SCHEMBL2013918 | 0.73 | MAPT (0.40) | SMN1; SMN2MAPTPOLBALDH1A1HSP90AA1 | |
| SCHEMBL2013627 | 0.73 | MAPT (0.46) | MAPTPOLBALDH1A1HSP90AA1KMT2A | |
| SCHEMBL2013353 | 0.72 | CACNA1G (0.45) | MAPTPOLBALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2513069-B1 | ANTIFUNGAL COMPOUNDS | UNIV LEUVEN KATH (BE) | 2014-10-15 | — | — | EP | claimed |
| EP-2513069-A1 | ANTIFUNGAL COMPOUNDS | Katholieke Universiteit Leuven (BE) | 2012-10-24 | — | — | EP | claimed |
| US-20120252801-A1 | ANTIFUNGAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2012-10-04 | — | — | US | claimed |
| WO-2011072345-A1 | ANTIFUNGAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2011-06-23 | — | — | WO | claimed |
| EP-2513069-B1 | ANTIFUNGAL COMPOUNDS | UNIV LEUVEN KATH (BE) | 2014-10-15 | — | — | EP | disclosed |
| EP-2513069-A1 | ANTIFUNGAL COMPOUNDS | Katholieke Universiteit Leuven (BE) | 2012-10-24 | — | — | EP | disclosed |
| US-20120252801-A1 | ANTIFUNGAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2012-10-04 | — | — | US | disclosed |
| US-20120252801-A1 | ANTIFUNGAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2012-10-04 | — | — | US | disclosed |
| WO-2011072345-A1 | ANTIFUNGAL COMPOUNDS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2011-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252801-A1 | ANTIFUNGAL COMPOUNDS | ERG28, DPM1, CYP51A1 | SMN1; SMN2 4701/4885MAPT 809/4885POLB 3581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.